Toxicology

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

Retrieved on: 
Wednesday, December 27, 2023
Biotechnology, Natural Resources, Pharmaceutical, General Health, Health, Mental Health, Cannabis, Clinical Trials, Toxicology, DRF, Metabolism, Research, Depression, Absorption, Psilocybin, HERG, Human, Addiction, Clinical trial, Disulfiram-like drug, Rat, ADR, Dog, Anxiety, Mental health, Animal, Cardiotoxicity, CNS, Safety, Therapy, Vomiting, Pharmaceutical industry

In addition, cardiac, respiratory, CNS safety pharmacology studies, an in vitro hERG current study, and genotoxicity studies have been completed and are undergoing analyses.

Key Points: 
  • In addition, cardiac, respiratory, CNS safety pharmacology studies, an in vitro hERG current study, and genotoxicity studies have been completed and are undergoing analyses.
  • Enveric expects to finalize all preclinical activities involving EB-373 in the first quarter of 2024 in preparation for a first-in-human clinical trial.
  • “Our research team has continued to diligently advance the preclinical program for our lead novel psilocin prodrug, EB-373, as we anticipate initiating first in human trials in 2024,” said Joseph Tucker, Ph.D., Director and CEO of Enveric.
  • Results from this study also demonstrated rapid conversion of EB-373 to the active metabolite psilocin, consistent with previously reported pharmacokinetic (PK) studies.

Philip Morris International Announces Senior Global Communications Leadership Changes

Retrieved on: 
Tuesday, December 19, 2023
Tobacco, Retail, Communications, Other Communications, Smoke, Global Communication, Marketing, Corporate Affairs, PMI, Culture, Toxicology, Food, Intellectual property, Life, ZYN, Woman, Sale, Research, Philip Morris International, IQOS, Doctor of Philosophy, University, Privacy, COVID-19, SVP, Information

Philip Morris International Inc. (PMI) (NYSE: PM) today announced senior management changes to further accelerate its rapid transition to a substantially smoke-free company.

Key Points: 
  • Philip Morris International Inc. (PMI) (NYSE: PM) today announced senior management changes to further accelerate its rapid transition to a substantially smoke-free company.
  • Effective January 1, 2024, Dr. Moira Gilchrist will be promoted to Chief Communications Officer and join PMI’s Senior Management Team.
  • Also effective January 1, 2024, Marian Salzman, currently SVP, Global Communications, will assume the position of SVP & Chief Corporate Citizenship Officer.
  • “She has been instrumental in shaping the strategy of PMI’s Global Communications function as we evolve the business and advance our smoke-free mission.

ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Research, GLP, Therapy, Toxicology, IND, Inflammasome, Clinical trial, Cholesterol, Tissue, Patient, ASC, Lipid, Marketing, VAR, Growth, NLRP3, Diabetic nephropathy, DKD, Government, Inflammation, Pharmaceutical industry, Vaccine, Cryptocurrency

WESTON, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today provides a corporate update, and reports financial results for the third quarter of 2023 ending September 30, 2023.

Key Points: 
  • WESTON, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today provides a corporate update, and reports financial results for the third quarter of 2023 ending September 30, 2023.
  • “The third quarter of 2023 marks substantial progress toward meeting a key milestone at ZyVersa, initiation of the first clinical trial with Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease, planned for Q1-2024.
  • Since its inception in 2014 through September 30, 2023, ZyVersa has not generated any revenue and has incurred significant operating losses and negative cash flows from its operations.
  • The net loss improvement was primarily due to lower costs incurred in connection with our research and development programs.

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, GLP, Food, Toxicology, IND, RAS, Verastem Oncology, Patient, Therapy, Cancer, Mutation, Pharmaceutical industry

Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential best-in-class KRAS G12D oral inhibitor as the lead program of its discovery and development collaboration with GenFleet Therapeutics (“GenFleet”).

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential best-in-class KRAS G12D oral inhibitor as the lead program of its discovery and development collaboration with GenFleet Therapeutics (“GenFleet”).
  • KRAS G12D represents 26% of all KRAS mutations, making it the most prevalent KRAS mutation in human cancer.
  • As previously announced, the discovery and development collaboration between Verastem Oncology and GenFleet aims to advance three oncology discovery programs related to RAS pathway-driven cancers.
  • The licenses would give Verastem Oncology development and commercialization rights outside of China while GenFleet would retain development and commercialization rights inside of China.

Estée Lauder Announces New Skin Longevity Initiative, The Next Frontier of Beauty

Retrieved on: 
Thursday, December 14, 2023
Research, Luxury, Women, Specialty, Health Technology, Consumer, Health, Cosmetics, Retail, Science, Diamond, Life expectancy, Editorial, Norm (mathematics), Aesthetics, Senior, Assistant professor, Reproductive system, Creative, Congress, Human, Movement, Life, Ageing, Style Design College, Ultimate Diamond, Public policy, Weill Cornell Medicine, Beauty, University of California, Berkeley, Skin, University, Global Brands Group, Sirtuin, Murphy, Toxicology, Stanford University, International Chinese Language Program, Biology, Pharmaceutical industry, Management, Psychology, List of life sciences, Dermatology, Medicine, Longevity

Estée Lauder today announces its new Skin Longevity platform, grounded in 15-years of expertise in pioneering skin longevity research.

Key Points: 
  • Estée Lauder today announces its new Skin Longevity platform, grounded in 15-years of expertise in pioneering skin longevity research.
  • Estée Lauder also announces its support of the Stanford Center on Longevity and its new Program on Aesthetics & Culture, whose work will include research assessing perceptions on longevity and vitality.
  • “The Estée Lauder brand has always been at the forefront of breakthrough skin science,” said Justin Boxford, Global Brand President, Estée Lauder.
  • Building on the brand’s commitment to furthering longevity research, Estée Lauder announces its support of the Stanford Center on Longevity, a cross-disciplinary research center at Stanford University.

Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan

Retrieved on: 
Friday, December 15, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Bridge loan, Safety, GMP, Engineering, Therapy, Technology transfer, Toxicology, Acceleration, Tularemia, National Research Council, FDA, Francisella tularensis, Infection, NRC, CMC, Biologics license application, Patent, TSX, Pharming, State, Drug development, Pharmaceutical industry

16/982,322 filed on September 18, 2020 and titled “A Method for Lyophilizing Live Vaccine Strains of Francisella Tularensis”.

Key Points: 
  • 16/982,322 filed on September 18, 2020 and titled “A Method for Lyophilizing Live Vaccine Strains of Francisella Tularensis”.
  • The patent covers the composition and preparation methods for the vaccine through 2039.
  • Appili licensed the biodefense vaccine candidate ATI-1701 from NRC in December 2017.
  • Under the amended terms, the Bridge Loan will now mature on March 31, 2024, subject to acceleration in connection with certain corporate events.

Philip Morris International Included in Dow Jones Sustainability World Index

Retrieved on: 
Tuesday, December 12, 2023
Professional Services, Retail, Environmental, Social and Governance (ESG), Environment, Tobacco, Sustainability, Smoke, S&P Global, Sale, Classification, S&P Dow Jones Indices, ISS, ZYN, IQOS, Research, NYSE, PMI, Food, WBCSD, Toxicology, Data, CSA, Dow Jones, Tobacco industry, Dow Jones Industrial Average, Bloomberg, Philip Morris International, SPGI, S&P, Growth, CDP, Life, ESG, Renewable energy

Philip Morris International Inc. (PMI) (NYSE: PM) has been included in the Dow Jones Sustainability™ World Index for the first time, and for the fourth consecutive year in the Dow Jones Sustainability™ North America Composite Index.1 The Dow Jones Sustainability™ World Index is one of the most reputable benchmarks for measuring the sustainability performance of companies worldwide, as identified by S&P Global through the annual Corporate Sustainability Assessment (CSA).

Key Points: 
  • Philip Morris International Inc. (PMI) (NYSE: PM) has been included in the Dow Jones Sustainability™ World Index for the first time, and for the fourth consecutive year in the Dow Jones Sustainability™ North America Composite Index.1 The Dow Jones Sustainability™ World Index is one of the most reputable benchmarks for measuring the sustainability performance of companies worldwide, as identified by S&P Global through the annual Corporate Sustainability Assessment (CSA).
  • The World Index includes the top 10% of the largest 2,500 companies in the S&P Global Broad Market Index based on long-term economic, environmental, and social criteria.
  • “Investors and other financial stakeholders place increasing value on reliable, robust, and timely measures of sustainability performance,” said Emmanuel Babeau, chief financial officer, PMI.
  • We are the only company in our sector included in the Dow Jones Sustainability™ World Index, leading the tobacco industry in this rating for the first time,” said Jennifer Motles, chief sustainability officer, PMI.

bit.bio further expands ioCells™️ range with early access launch of ioMotor Neurons™️ for research and drug discovery in diseases such as amyotrophic lateral sclerosis (ALS)

Retrieved on: 
Wednesday, December 6, 2023
Health, Stem Cells, Genetics, Research, Science, Pharmaceutical, Biotechnology, CNS, ALS, Motor neuron diseases, Toxicology, Patient, Multimedia, Culture, Weakness, Automation, Motor neuron, Drug discovery, Neuron, Cell, CRISPR, Death, Brain cell, Innovation, Aroma compound, Pharmaceutical industry, Medical device

This takes the total number of products in the ioCells range - human cells for research and drug discovery - to 20 products, including wild type, CRISPR-ready and disease model cells.

Key Points: 
  • This takes the total number of products in the ioCells range - human cells for research and drug discovery - to 20 products, including wild type, CRISPR-ready and disease model cells.
  • The launch of ioMotor Neurons also follows the recent opening of bit.bio’s new manufacturing and automation laboratories by the UK’s Minister for Science, Research and Innovation.
  • Damage or death of motor neurons can lead to a devastating group of conditions called Motor Neuron Diseases (MNDs).
  • ioMotor Neurons are an important part of our ALS toolkit that can now be incorporated into motor neuron disease research and early drug discovery workflows in ways that were not previously possible.

Philip Morris International Inc. Declares Regular Quarterly Dividend of $1.30 Per Share

Retrieved on: 
Thursday, December 7, 2023
Tobacco, Retail, Smoke, Sale, ZYN, IQOS, Research, NYSE, PMI, Food, Swedish Match, Life, Toxicology, Philip Morris International, Sportsheets International, Inc.

The Board of Directors of Philip Morris International Inc. (NYSE: PM) today declared a regular quarterly dividend of $1.30 per common share, payable on January 10, 2024, to shareholders of record as of December 21, 2023.

Key Points: 
  • The Board of Directors of Philip Morris International Inc. (NYSE: PM) today declared a regular quarterly dividend of $1.30 per common share, payable on January 10, 2024, to shareholders of record as of December 21, 2023.
  • For more details on stock, dividends and other information, see www.pmi.com/dividend .
  • Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector.
  • For more information, please visit www.pmi.com and www.pmiscience.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20231206692360/en/

Philip Morris International Inc. Presents at 2023 Morgan Stanley Global Consumer & Retail Conference

Retrieved on: 
Tuesday, December 5, 2023
Tobacco, Retail, Specialty, Smoke, Sale, ZYN, Woman, IQOS, Research, PMI, Food, Swedish Match, Toxicology, Privacy, Intellectual property, Marketing, COVID-19, Philip Morris International, Life, Information, Risk management

In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements.

Key Points: 
  • In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements.
  • Future results are also subject to the lower predictability of our reduced-risk product category's performance.
  • PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties.
  • Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector.